The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

Amy E. Moran, Magdalena Kovacsovics-Bankowski, Andrew D. Weinberg

Research output: Contribution to journalReview articlepeer-review

125 Scopus citations


T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.

Original languageEnglish (US)
Pages (from-to)230-237
Number of pages8
JournalCurrent opinion in immunology
Issue number2
StatePublished - Apr 2013
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this